Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

termittent dosing by both subcutaneous injection and brief (1-2 hour) intravenous (IV) infusion. The maximally tolerable dose (MTD) on a once-per-week for 3 weeks schedule was identified. The follow-on study using the MTD administered on a twice-per- week for 3 weeks schedule has also been completed.

Genta expects to incorporate this new schedule into the ongoing melanoma trial with Abraxane(R) and Temodar(R). These new schedules may ultimately obviate the need for treatment via continuous IV infusion. Abstracts describing results of these studies have been submitted to the 2008 ASCO meeting.

G4544, A New Oral Drug for Skeletal Diseases, Enters Clinical Trials

In late 2007, Genta completed the initial Phase 1 study of G4544, the Company's proprietary small molecule that is intended to treat diseases associated with accelerated bone loss. G4544 contains the active ingredient in Ganite(R), a highly effective drug whose market potential has been constrained by a requirement for continuous IV infusion. No drug-related adverse experience was observed in 30 subjects who received G4544 over a 5- fold dosing range. Further clinical and pharmacokinetic results have been submitted to the 2008 ASCO meeting.

G4544 Development Strategy: The Company has improved the G4544 manufacturing process. Following review and approval of this change, Genta will seek FDA guidance on the 505(b)(2) regulatory pathway, which may shorten development time by allowing use of bioequivalence studies rather than trials to demonstrate efficacy and safety. In this case, Genta owns the NDA for Ganite and has exclusive ownership of important trade secrets, including but not limited to detailed pharmacokinetics and long-term animal toxicology of the active ingredient. The 505(b)(2) approach enables potential approval in the currently approved indication (cancer-related hypercalcemia), in parallel with development in other indications. Low doses of the active ingredient have als
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 Pulse Light ... a survey to Rosacea sufferers as part of their ongoing ... Rosacea sufferers found effective for their Rosacea. The survey participants ... comprised 47% men and 53% women. The results ... participants did not consider or attempt to visit their GP ...
(Date:6/30/2015)... , June 30, 2015  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that the ... 14, 2015, from 8:00 a.m.- 1:00 pm EDT in ... The Ardelyx senior management team will present an ... compound, tenapanor, which has completed Phase 2b clinical trials ...
(Date:6/30/2015)... , BERKELEY, Kalifornien, und KOPENHAGEN, Dänemark, ... Biologics, Inc. , ein Weltmarktführer der klinischen ... anderen therapeutischen Proteinen, gab heute bekannt, dass ... der Produktionskapazität den Ausbau der nordamerikanischen Produktionsanlage ... mit der Ergänzung  einer Einweg-Anlage Bioreactor 6Pack™ ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3
... Mass., Oct. 26, 2011 Idenix Pharmaceuticals, Inc. (NASDAQ: ... financial results for the third quarter of 2011 on Wednesday, ... Idenix management will host a conference call at 4:30 p.m. ... financial results for the third quarter of 2011 and provide ...
... MECHANICSBURG, Pa., Oct. 26, 2011 One out of three ... according to an Opinion Research/Select Medical telephone poll. Against that ... a statement today reminding the American public that influenza season ... chronic lung disease such as asthma or COPD (Chronic Obstructive ...
Cached Medicine Technology:Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD) 2Poll: One Out of Three U.S. Adults Not Planning to Get Flu Shot This Year 2
(Date:6/30/2015)... ... June 30, 2015 , ... ... “Fireside Convalescent Care Center.” The video informs community members of Fireside’s Five-Star Medicare ... the need for those seeking care to be well informed and confident about ...
(Date:6/30/2015)... , ... June 30, 2015 , ... The LIV ... on fertility preservation and deciding the right age to pursue egg freezing. Statistics show ... the age of 35 — a 150 percent increase since the 1970s. , Sadly, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Today, Grand Terrace Health Care ... Care Center.” Each year, Medicare ranks care centers around the country in an ... their needs. Grand Terrace prides itself on quality in each of Medicare’s evaluation ...
(Date:6/30/2015)... ... June 30, 2015 , ... According to a recent ... to 2013 while heroin-related deaths more than tripled in the same period—leading a majority ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, asserts that these ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... announces today that they have been awarded the exclusive billing agreements with Jackson ... range of billing services encompassing their proprietary suite of billing process software functionality ...
Breaking Medicine News(10 mins):Health News:Fireside Convalescent Hospital Proves Itself as a Leading Care Center in New Video 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 4Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 5Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2
... 1, 2010) Robotic surgical technology with its ... touch, even as they operate from a remote ... intersensory integration, and reports that surgical outcomes for ... compare favorably with traditional invasive surgery. Led by ...
... better than a "salt tax," study finds , MONDAY, ... to reduce U.S. sodium consumption by as little as ... of dollars, according to new research. , Cutting salt ... attacks and stroke. , "Per person on average it ...
... Mediterranean regimens all help the heart, study finds , ... three heart-healthy diets -- low-fat, low-carbohydrate, Mediterranean -- can ... to heart attack and stroke, an Israeli study indicates. ... though you experience only a moderate weight loss, if ...
... apt to enhance verbal skills, experts say, , MONDAY, ... their infants in front of supposedly brain-enhancing DVDs in ... be accomplishing nothing, new research shows. , What,s more, ... DVDs at an earlier age actually had lower levels ...
... , ... ... ... ...
... ... ... , , ... DALLAS , March ...
Cached Medicine News:Health News:Prostate cancer surgeons 'feel' with their eyes 2Health News:Prostate cancer surgeons 'feel' with their eyes 3Health News:Cutting Salt Could Prevent Almost 500,000 Heart Attacks 2Health News:Cutting Salt Could Prevent Almost 500,000 Heart Attacks 3Health News:Popular Diet Plans Can Unclog Arteries 2Health News:Watching Special Videos May Not Make Kids Brainier 2Health News:Watching Special Videos May Not Make Kids Brainier 3Health News:GNC Says 'Thank You' to Customers and Employees for Their $1.4 Million in Donations to the Sixth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Health News:GNC Says 'Thank You' to Customers and Employees for Their $1.4 Million in Donations to the Sixth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Health News:GNC Says 'Thank You' to Customers and Employees for Their $1.4 Million in Donations to the Sixth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 4Health News:GNC Says 'Thank You' to Customers and Employees for Their $1.4 Million in Donations to the Sixth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 5Health News:National Sleep Awareness Week(R) (March 7-13): How Are You Sleeping? 2Health News:National Sleep Awareness Week(R) (March 7-13): How Are You Sleeping? 3Health News:National Sleep Awareness Week(R) (March 7-13): How Are You Sleeping? 4Health News:National Sleep Awareness Week(R) (March 7-13): How Are You Sleeping? 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: